Lung-RADS Category 4A means a nodule found on your lung cancer screening CT scan is suspicious enough that your doctors want to take a closer look, typically with a repeat scan in about three months. It sits in the lower end of the “suspicious” range, and while the word “suspicious” can feel alarming, the actual chance that a 4A nodule turns out to be cancer varies widely across studies, from roughly 6% to about 16% depending on the patient population. That leaves a large majority of 4A findings as false alarms, but the probability is high enough that ignoring them is not an option.
What Puts a Nodule Into Category 4A
Lung-RADS is a scoring system created by the American College of Radiology to standardize how radiologists report findings from low-dose CT (LDCT) lung cancer screening scans. The categories run from 0 (incomplete scan) through 4 (suspicious), and the system’s whole purpose is to sort nodules by how worried everyone should be. Category 1 means negative, category 2 means benign-appearing, category 3 means “probably benign but let’s check again in six months,” and category 4 is where real suspicion begins.
Within category 4, there are three tiers: 4A, 4B, and 4X. A solid nodule generally lands in 4A when it measures between about 8 and 15 mm on a new scan, or when a previously seen solid nodule has grown to that range. Part-solid nodules with a solid component of 6 mm or more can also qualify. The 2022 revision of the system also added some specific findings to 4A, including thick-walled and multilocular cysts when they have a solid component of at least 8 mm.1Journal of the American College of Radiology. ACR Lung-RADS v2022: Assessment Categories and Management Recommendations – Section: New Classification Criteria That version also clarified how to handle juxtapleural nodules (those sitting against the lining of the lung), airway-centered nodules, and findings that look like infection or inflammation rather than cancer.2PubMed. Lung-RADS v2022 Update
The key thing to understand is that 4A captures nodules in a gray zone. They are large or distinctive enough that the radiologist cannot confidently call them benign, but they have not yet reached the size or appearance that pushes them into the more alarming 4B or 4X tiers. The practical consequence is a specific follow-up recommendation rather than an immediate rush to biopsy.
The Actual Chance of Cancer
The malignancy rate for Lung-RADS 4A nodules is one of the most researched questions in lung screening, and the numbers bounce around depending on the study. In a study from a university-based screening program, only about 6% of 4A nodules turned out to be malignant, compared to roughly 20% for 4B and 71% for 4X.3PubMed. Characterizing Lung-RADS category 4 lesions in a university lung cancer screening program Another clinical practice study reported a higher figure of about 16% for 4A, with 4B at 36% and 4X at 77%.4PubMed. Lung-RADS Category 3 and 4 Nodules on Lung Cancer Screening in Clinical Practice A retrospective analysis of the large National Lung Screening Trial found that about 27% of all screen-detected cancers fell into the 4A category, though the overall cancer prevalence at the 4A level was still relatively low compared to 4B, where it climbed to roughly 35%.5PubMed Central. Performance of Lung-RADS in the National Lung Screening Trial: A Retrospective Assessment
Why the range? The populations differ. Screening programs at academic medical centers, community hospitals, and VA systems all draw from different mixes of people with varying smoking histories, exposure risks, and regional disease patterns. In areas where granulomatous disease is common (from infections like histoplasmosis or tuberculosis), benign nodules that mimic suspicious findings are more frequent, which drives down the malignancy rate within any given category.6Semantic Scholar. Lung-RADS used in Lung Cancer Screening: Does granulomatous disease make a difference in a developing country? Still, the broad takeaway holds: a 4A result means roughly a 1-in-7 to 1-in-16 chance of cancer, depending on context. That is low enough to avoid panic but high enough to demand timely follow-up.
How 4A Compares to 4B and 4X
The gap between the category 4 subtiers is not small. In the university screening study, the odds of malignancy jumped nearly fourfold going from 4A to 4B, and nearly 40-fold going from 4A to 4X.3PubMed. Characterizing Lung-RADS category 4 lesions in a university lung cancer screening program Category 4B typically applies to larger nodules (solid nodules 15 mm or bigger, for example) or to part-solid nodules with bigger solid components. Category 4X is a modifier that a radiologist applies when additional features raise suspicion beyond what the size alone would suggest, such as spiculated margins, lymph node enlargement, or rapid growth since a prior scan.
In a study looking specifically at subsolid nodules (the hazy, ground-glass type), the malignancy rate for 4X reached 46% to 57% depending on the radiologist, compared to about 19% for 4A and 23% for 4B in that particular nodule type.7PubMed Central. Lung-RADS Category 4X: Does It Improve Prediction of Malignancy in Subsolid Nodules? The practical difference is that 4B and 4X nodules usually skip the “wait and re-scan” step entirely and go straight to diagnostic chest CT, PET/CT, or biopsy. A 4A designation, by contrast, buys time for observation.
What Happens After a 4A Result
The standard recommendation under Lung-RADS is a follow-up low-dose CT scan in about three months.8PubMed Central. Malignant Nodules Detected on Lung Cancer Screening CT: Yield of Short-Term Follow-Up CT in Showing Nodule Growth This short interval is designed to catch whether the nodule is growing. If it stays the same size or shrinks, that is reassuring and often leads to a step-down to routine annual screening. If it grows, your team will likely recommend more aggressive workup: a diagnostic CT with contrast, a PET/CT to look for metabolic activity, or a tissue biopsy.
For certain 4A nodules with specific features, PET/CT can be part of the initial workup rather than waiting the full three months. The 2022 Lung-RADS update explicitly mentions PET/CT as an option for thick-walled cysts with a solid component of 8 mm or more.1Journal of the American College of Radiology. ACR Lung-RADS v2022: Assessment Categories and Management Recommendations – Section: New Classification Criteria Your radiologist and pulmonologist will factor in the nodule’s shape, density, location, and your personal risk profile when deciding which path to take.
The Debate Over Three-Month Follow-Up
The three-month re-scan interval for 4A is not universally loved among radiologists. Research looking at how often that three-month scan actually shows meaningful growth has found the yield to be low. Many nodules that are truly cancerous may not grow detectably in just 90 days, especially if the cancer is slow-growing. One study examining this question recommended that radiologists maintain a low threshold for initially assigning 4X instead of 4A when any worrying features are present, because doing so fast-tracks diagnostic workup and can lead to earlier cancer diagnoses. The same researchers suggested that when a nodule genuinely belongs in 4A with no additional concerning features, a longer follow-up interval than three months might actually work better, giving a slow-growing cancer more time to declare itself through visible growth.8PubMed Central. Malignant Nodules Detected on Lung Cancer Screening CT: Yield of Short-Term Follow-Up CT in Showing Nodule Growth
This matters because the three-month scan can sometimes give false reassurance. If the nodule is stable at three months but actually harbors a slow cancer, you might feel relieved and drop your guard. Meanwhile, a six-month scan might have shown clear growth that would have prompted action. The field is still working through this tension, and the official Lung-RADS recommendation remains three months for now, but your doctor may adjust the timing based on your individual situation.
How Fast Nodules Grow and Why It Matters
Growth rate is one of the most important clues in figuring out whether a nodule is cancerous. Radiologists think about this in terms of volume doubling time, which is how long it takes a nodule to double its three-dimensional volume. A study comparing benign and malignant growing nodules found that malignant solid nodules doubled in volume in a median of about 204 days, while benign growing solid nodules took about 386 days. Among malignant solid nodules that were growing, 92% had a doubling time under 400 days, compared to 58% of benign growing nodules.9PubMed Central. Volume Doubling Times of Benign and Malignant Nodules in Lung Cancer Screening
For you as a patient, the implication is straightforward: if your follow-up scan shows your nodule has grown quickly, the level of concern rises. If it is stable or growing very slowly, that tilts the odds toward benign. But the overlap between benign and malignant growth rates is real, which is why growth alone does not settle the question. It is one piece of evidence among several.
Different Radiologists, Different Readings
A reality of Lung-RADS that rarely gets discussed in patient-facing materials is that two radiologists reading the same scan do not always assign the same category. In a study where seven experienced radiologists independently read 160 screening CT scans, they disagreed about the Lung-RADS category in roughly 29% of reading pairs. About 8% of those disagreements led to a meaningful difference in the recommended next step (such as one reader calling for a three-month follow-up while another said annual screening was fine). Most of the disagreements were not about measuring the same nodule differently but about which nodule each reader chose as the most concerning one on the scan.10PubMed Central. Observer variability for Lung-RADS categorisation of lung cancer screening CTs: impact on patient management
Technology is helping close this gap. When radiologists use semiautomated measurement tools instead of measuring nodules manually with calipers, agreement improves substantially. One study found that switching from manual measurement to computer-assisted volumetric measurement pushed inter-reader agreement to a kappa of 0.81 or higher across all Lung-RADS classifications.11PubMed Central. Improved Interobserver Agreement on Lung-RADS Classification of Solid Nodules Using Semiautomated CT Volumetry A separate study comparing standard viewing software to a dedicated lung screening viewer found that the dedicated tool lifted agreement from moderate to substantial.12PubMed Central. Assisted versus Manual Interpretation of Low-Dose CT Scans for Lung Cancer Screening: Impact on Lung-RADS Agreement
What does this mean if you have been told you have a 4A nodule? It means your category assignment is a well-informed professional judgment, but it is not a lab test with a single correct answer. If you are borderline between categories, a second opinion or a reading with volumetric software could reasonably shift your classification in either direction. That does not mean the system is broken. It means borderline cases are inherently ambiguous, and the system is designed to err on the side of caution.
How You Will Hear About Your Results
The way screening results reach patients varies widely. A national survey of Veterans Health Administration screening programs found that a Lung-RADS 4 result was typically communicated by letter plus phone call at about 56% of facilities, and by phone call alone at the rest.13Chest. Communication of Lung Cancer Screening Results: A National Survey of Veterans Health Administration Facilities Some programs conduct shared decision-making conversations before screening even begins, often by phone (53% of the time in that survey), sometimes mailing a written decision aid beforehand so patients can think through the implications before talking to a clinician.
If you receive a 4A result, you should expect a follow-up conversation with your doctor explaining the finding and the plan. If that conversation does not happen and you simply receive a letter, call the ordering physician’s office. A 4A result is not an emergency, but it does require a defined next step. You do not want it to fall through the cracks because a letter sat unopened or a voicemail was missed.
AI and the Future of Sorting Suspicious Nodules
One of the frustrations with the current system is that 4A captures a wide net of nodules, most of which are benign. Researchers are working on tools to sharpen the distinction. A recent study tested a multimodal approach combining a special type of MRI with CT-based radiomics (computer-extracted features from the scan images) and clinical factors like nodule diameter and calcification. The combined model achieved strong discriminating performance for distinguishing benign from malignant nodules rated 4A or higher, outperforming any single imaging approach alone.14PubMed Central. A multimodal nomogram for benign-malignant discrimination of lung-RADS ≥4A nodules: integration of oxygen enhanced zero echo time MRI, CT radiomics, and clinical factors Another study fused deep learning algorithms with radiomics specifically for Lung-RADS 3 and 4A nodules and showed improved accuracy for sorting benign from malignant findings, with the goal of reducing unnecessary procedures for people whose nodules are harmless while catching real cancers sooner.15PubMed Central. Fusion of 2.5D deep transfer learning and radiomics for predicting benign and malignant Lung Imaging Reporting and Data System (Lung-RADS) 3 and 4A nodules
These tools are not yet standard clinical practice, but they represent where the field is heading. The ideal outcome would be a system that takes a 4A nodule and gives you a much more personalized risk estimate rather than a broad “somewhere between 6% and 16% chance.” That kind of precision could spare many people the anxiety and radiation exposure of repeated scans while ensuring that actual cancers get caught earlier.
When Screening Catches Something Versus When It Creates Anxiety
Lung cancer screening with LDCT saves lives by catching cancers at earlier, more treatable stages. But the trade-off is that screening also finds an enormous number of things that look suspicious but turn out to be nothing. Across all the Lung-RADS categories, the vast majority of flagged nodules are benign. Category 4A sits right in the zone where this tension is sharpest: the chance of cancer is real but minority, and the chance of a false alarm is high.
Living with that uncertainty for three months (or longer, if your doctors opt for extended follow-up) is genuinely stressful. Some people describe the waiting period as worse than the scan itself. If you find yourself in that position, it helps to anchor on the numbers: even at the higher end of malignancy estimates, roughly five out of six 4A nodules are not cancer. And among the ones that are, many are caught early enough for curative treatment. The system is designed so that the cost of watching a nodule a bit longer is small compared to the benefit of avoiding unnecessary surgery on a nodule that was never a threat. That logic does not make the wait easy, but it does make it rational.
If you have a 4A result and are not sure what comes next, ask your doctor three questions: what does the nodule look like on the scan, when is your follow-up imaging scheduled, and what would change the plan? Those answers give you a concrete framework and a timeline, which is usually more helpful than searching for statistics online at 2 a.m.
Who Gets Screened in the First Place
Lung-RADS categories only come into play for people undergoing organized lung cancer screening, which under current U.S. guidelines is recommended for adults aged 50 to 80 with a 20-pack-year smoking history who currently smoke or quit within the past 15 years. Those thresholds, however, are not equal in their impact across all populations. Research has shown that the standard eligibility criteria may under-screen Black individuals, who develop lung cancer at higher rates at younger ages and with lighter smoking histories. One study found that reducing the minimum screening age to 43 and the smoking-history threshold to 15 pack-years for Black individuals equalized their odds of screening eligibility with White individuals under the current criteria.16PubMed Central. Revisiting the lung cancer screening eligibility criteria to promote equity for Black individuals Whether screening guidelines will eventually adopt race-specific or risk-model-based criteria is an active area of debate, but the point is relevant here: if you are at elevated risk for lung cancer but fall outside current screening eligibility, a Lung-RADS category may never enter your medical record simply because no one ordered the scan.